BR112022024195A2 - Anticorpos anti-tgfss e usos terapêuticos dos mesmos - Google Patents
Anticorpos anti-tgfss e usos terapêuticos dos mesmosInfo
- Publication number
- BR112022024195A2 BR112022024195A2 BR112022024195A BR112022024195A BR112022024195A2 BR 112022024195 A2 BR112022024195 A2 BR 112022024195A2 BR 112022024195 A BR112022024195 A BR 112022024195A BR 112022024195 A BR112022024195 A BR 112022024195A BR 112022024195 A2 BR112022024195 A2 BR 112022024195A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- therapeutic uses
- tgfss
- tgfß
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036092P | 2020-06-08 | 2020-06-08 | |
| PCT/US2021/036347 WO2021252455A1 (en) | 2020-06-08 | 2021-06-08 | ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024195A2 true BR112022024195A2 (pt) | 2023-02-07 |
Family
ID=76708478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024195A BR112022024195A2 (pt) | 2020-06-08 | 2021-06-08 | Anticorpos anti-tgfss e usos terapêuticos dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220119513A1 (https=) |
| EP (1) | EP4161654A1 (https=) |
| JP (1) | JP7798805B2 (https=) |
| KR (1) | KR20230022974A (https=) |
| CN (1) | CN115803342A (https=) |
| AU (1) | AU2021287868A1 (https=) |
| BR (1) | BR112022024195A2 (https=) |
| CA (1) | CA3186707A1 (https=) |
| CO (1) | CO2023000068A2 (https=) |
| DK (1) | DK202370008A1 (https=) |
| MX (1) | MX2022015609A (https=) |
| PH (1) | PH12022500030A1 (https=) |
| WO (1) | WO2021252455A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038522A (ko) | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| MX2023003624A (es) | 2020-09-28 | 2023-04-11 | Zoetis Services Llc | Variantes de anticuerpos caninos. |
| CA3232382A1 (en) * | 2021-09-27 | 2023-03-30 | Zoetis Services Llc | Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof |
| WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| US20240209096A1 (en) | 2022-12-27 | 2024-06-27 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| AU2024210302A1 (en) | 2023-01-20 | 2025-09-04 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| CN117106082B (zh) * | 2023-09-15 | 2024-10-29 | 成都蓉生药业有限责任公司 | 一种抗TGFβ的人源化纳米抗体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5350576A (en) | 1991-09-13 | 1994-09-27 | Mycogen Corporation | Bacillus thuringiensis isolates for controlling acarides |
| US6194167B1 (en) | 1997-02-18 | 2001-02-27 | Washington State University Research Foundation | ω-3 fatty acid desaturase |
| MXPA01009363A (es) | 1999-03-18 | 2002-06-04 | Merck Patent Gmbh | Proteina para bloquear la adhesion de plaquetas. |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1130098A3 (en) | 2000-02-29 | 2003-09-10 | Pfizer Products Inc. | Mammalian osteoregulins |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| US7261890B2 (en) | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| EP1966243B1 (en) * | 2005-12-23 | 2012-02-15 | Eli Lilly And Company | Tgf-beta binding antibodies |
| US9518112B2 (en) * | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
| LT2971048T (lt) * | 2013-03-11 | 2019-02-25 | Genzyme Corporation | Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) * | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI787230B (zh) * | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| WO2018208670A1 (en) * | 2017-05-08 | 2018-11-15 | Trustees Of Tufts College | EXTRACELLULAR VESICLES COMPRISING MEMBRANE-TETHERED TGF-β, COMPOSITIONS AND METHODS OF USE THEREOF |
| CN113613725B (zh) * | 2018-11-05 | 2025-09-23 | 路德维格癌症研究所有限公司 | 人源化和变体TGF-β1特异性抗体及其方法和用途 |
-
2021
- 2021-06-07 US US17/341,212 patent/US20220119513A1/en active Pending
- 2021-06-08 KR KR1020237000721A patent/KR20230022974A/ko active Pending
- 2021-06-08 JP JP2022576392A patent/JP7798805B2/ja active Active
- 2021-06-08 WO PCT/US2021/036347 patent/WO2021252455A1/en not_active Ceased
- 2021-06-08 EP EP21736479.3A patent/EP4161654A1/en active Pending
- 2021-06-08 BR BR112022024195A patent/BR112022024195A2/pt unknown
- 2021-06-08 CN CN202180049397.1A patent/CN115803342A/zh active Pending
- 2021-06-08 AU AU2021287868A patent/AU2021287868A1/en active Pending
- 2021-06-08 PH PH1/2022/500030A patent/PH12022500030A1/en unknown
- 2021-06-08 CA CA3186707A patent/CA3186707A1/en active Pending
- 2021-06-08 MX MX2022015609A patent/MX2022015609A/es unknown
-
2023
- 2023-01-05 CO CONC2023/0000068A patent/CO2023000068A2/es unknown
- 2023-01-06 DK DKPA202370008A patent/DK202370008A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230022974A (ko) | 2023-02-16 |
| CA3186707A1 (en) | 2021-12-16 |
| AU2021287868A1 (en) | 2022-12-22 |
| CO2023000068A2 (es) | 2023-01-16 |
| PH12022500030A1 (en) | 2024-02-26 |
| US20220119513A1 (en) | 2022-04-21 |
| EP4161654A1 (en) | 2023-04-12 |
| CN115803342A (zh) | 2023-03-14 |
| DK202370008A1 (en) | 2023-01-31 |
| JP7798805B2 (ja) | 2026-01-14 |
| MX2022015609A (es) | 2023-04-20 |
| WO2021252455A1 (en) | 2021-12-16 |
| JP2023530663A (ja) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022024195A2 (pt) | Anticorpos anti-tgfss e usos terapêuticos dos mesmos | |
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| BR112022026341A2 (pt) | Anticorpos e métodos para o tratamento de doenças associadas à claudina | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BRPI0514395A (pt) | uso terapêutico de inibidores de rtp801 | |
| BR112022018667A2 (pt) | Composições e métodos para inibir a expressão de ang-ptl3 | |
| Casanueva et al. | Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients | |
| BR112016018205A2 (pt) | métodos de tratamento de mal de alzheimer | |
| BR112021025421A2 (pt) | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos | |
| BR112021023487A2 (pt) | Moléculas de ligação anti-tdp-43 e usos das mesmas | |
| CL2008002565A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente al dominio extracelular de cxcr5/receptor de linfoma de burkitt (blr1)/cd185/mdr15/mgc117347 humano; molécula de ácido nucleico aislada que lo codifica; vector que comprende a dicha molécula de ácido nucleico; célula huésped aislada que comprende a dicho vector; uso médico de dicho anticuerpo; y composición farmacéutica que lo comprende. | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| BR112016009797A2 (pt) | anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos | |
| BR112013017446A2 (pt) | composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona | |
| BR112019000098A2 (pt) | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio | |
| BRPI0514288A (pt) | benzamidas substituìdas com triflúor-metila como inibidores de cinases | |
| BR112021018262A2 (pt) | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina | |
| BR112023001061A2 (pt) | Anticorpos antiabeta | |
| BR112021017810A2 (pt) | Anticorpos tsg-6 e usos dos mesmos | |
| BR112021025383A2 (pt) | Metiltionínio para uso no tratamento de sinaptopatias | |
| ECSP21082527A (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
| Attilio et al. | The effects of blast exposure on protein deimination in the brain | |
| BR112022020742A2 (pt) | Anticorpo anti-ox40 e usos do mesmo | |
| BR112023002234A2 (pt) | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 | |
| BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral |